TKNO News & Events

Reports Q4 revenue $9.98M, consensus $9.61M. "After another successful year of disciplined execution against our strategic objectives, we've decided to further invest in our commercial capabilities this year," said Stephen Gunstream, President and Chief Executive Officer at Teknova. He continued, "As we begin to realize the benefits of the substantial capital investments we've made in recent years, and amid signs that the biotech funding environment is likely to continue to improve, we believe that additional and targeted commercial efforts should enable us to become Adjusted EBITDA positive by the end of 2027."

The company said, "Teknova anticipates total revenue of $42 million to $44 million for the fiscal year ending December 31, 2026. The Company also anticipates Free Cash Outflow of less than $10 million for 2026."

The company said, "Teknova reiterates its fiscal 2025 outlook for revenue and Free Cash Outflow. The Company continues to anticipate total revenue of $39 million to $42 million for the fiscal year ending December 31, 2025. The Company also anticipates Free Cash Outflow of less than $12 million for 2025."

Reports Q3 revenue $10.45M, consensus $10.23M. "We had a strong third quarter, our fifth consecutive quarter of year-over-year revenue growth, despite a very challenging funding backdrop for small- to mid-size biotech companies," said Stephen Gunstream, President and Chief Executive Officer at Teknova. "Notwithstanding those challenges, the number of our Clinical Solutions customers continues to rise. We believe that our relationships with those customers, paired with our diverse Lab Essentials product portfolio and customer base, position us for long-term, sustainable, above-market growth."